Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 14/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821953 | 0.93 | LMNA (0.54) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL1909166 | 0.92 | GRM2 (0.53) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL28595790 | 0.90 | ESR1 (0.55) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL3092869 | 0.89 | HSD17B10 (0.51) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL554548 | 0.89 | GRM2 (0.51) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL553801 | 0.89 | GRM2 (0.53) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL30739239 | 0.88 | GRM2 (0.50) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL30739426 | 0.88 | GRM2 (0.50) | KLKB1GRM2LMNANPC1ALDH1A1 | |
| SCHEMBL3093449 | 0.88 | GRM2 (0.63) | KLKB1GRM2LMNAALDH1A1 | |
| SCHEMBL553854 | 0.88 | HSD17B10 (0.60) | KLKB1GRM2LMNANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | KLKB1 2/4885GRM2 4059/4885LMNA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.